Since Herceptin’s approval in 1998, breast cancer has moved from a near-term death sentence to, in many cases, a chronic disease. Pancreatic cancer is now drawing the same comparison.
Endpoints News, reporting from San Diego, is calling a recent development the disease’s long-awaited breakthrough.
The parallel to 1998 is the key argument. Herceptin didn’t just extend survival; it changed what a breast cancer diagnosis meant over the following decades. If pancreatic cancer follows a comparable path, clinicians and patients would be looking at a very different treatment reality.
A shift of the scale Herceptin produced in breast cancer would match Herceptin’s own 1998 approval as a watershed moment in oncology.
The Herceptin comparison is a high bar. Whether pancreatic cancer follows a similar arc is now an open question for oncologists and regulators alike. The answer will depend on whether the current data holds and expands over the coming years.
Sarah Chen